CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. - Wikidata - wikimedia - TriplyDB

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

http://www.wikidata.org/entity/Q35834087

about

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.Prioritization schema for immunotherapy clinical trials in glioblastoma.A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.Role of Natural Killer Cells in HIV-Associated Malignancies.Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Driving gene-engineered T cell immunotherapy of cancer.Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.Retroviral Vectors for Cancer Gene Therapy.Immune and viral therapies for malignant primary brain tumors.Modeling Natural Killer Cell Targeted Immunotherapies.Engineering Natural Killer Cells for Cancer Immunotherapy.Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.Leveraging natural killer cells for cancer immunotherapy.Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.The Broad Spectrum of Human Natural Killer Cell Diversity.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.Current Status of Gene Engineering Cell Therapeutics.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.NK-92 cell, another ideal carrier for chimeric antigen receptor.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Tumor immunotherapy: New aspects of natural killer cells.Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

P2860

Q26751020-14AEA542-E6CC-4F90-8D6A-BB0256C87626 Q28069424-FB198DEA-1723-456B-88C9-B4497DCC3E02 Q28079180-6C06A909-28CB-4819-8A98-D901344F9556 Q33594333-80680003-720A-4BF4-BE36-74FC110AF0F7 Q33700795-4F14DE51-6D14-473F-8978-C9B5B7DB0076 Q36821054-24A739C1-6D80-4AA2-8B7A-A713ED3BF937 Q37078999-56E1290B-0B5B-4E6D-BB29-4AC812FDDC32 Q37317390-208464A9-2FD3-46C8-9116-DC14EF164BC3 Q37712593-7C2ACC7F-6A39-470E-B9F6-99066B96B824 Q38656009-563D4254-64BD-4CED-89A1-CEBA62E045F1 Q38666862-5EB17F1D-5DA5-4FF4-ACC5-EAE11F6D3895 Q38685785-E81EB9FC-F8CC-44EF-A3F4-385254967E5B Q38777742-FC5FFF63-0A8C-4383-AEC2-BC1597776982 Q39045586-8D80903A-280D-4A1B-8EEE-840B47F949E8 Q39094431-4DC60E3A-6320-478A-A90E-16F3CD06C59F Q39168899-F2848A72-8412-42AB-9400-FC96A17CF459 Q39239278-D319EB82-393C-428E-A2F6-62ED8EB50C26 Q39408704-57240511-8A87-4FF9-AE55-879D041153A8 Q40393182-28E503EB-74B1-437C-99F5-DEEF26366229 Q41619501-CC8874F3-16C7-4F76-86A7-CA05AB8BC75F Q41684097-B29FD3E0-AC56-4B86-BD66-5B90245EDCB4 Q42684428-A35FE9D8-4D3E-47C2-BAA3-BCD443B62829 Q43695979-7E62ECEE-74C7-4270-A453-3F81D5C01DE3 Q43865719-A16DC0B7-2E4E-4EEE-863D-923F21D3DC45 Q46366459-9A4321E2-9047-44C2-8983-34BFB1332757 Q47373461-5156E05B-782A-4159-80C3-9679B334C26E Q47681829-05096219-54B4-4EA0-8435-CAF3D986EF11 Q47843897-0E89D233-FCD3-499F-ABCD-BBC91FAD339D Q48504970-BB54C430-EF7B-44C6-8960-A665A91FEFE5 Q49829282-8EBB5294-1E13-4A17-AED5-69877EBBF875 Q49887903-56961676-3BB0-4F42-BD7A-460427A0032F Q50027824-3087F52F-25EE-49C2-870F-AE4C8B202111 Q50100856-203902DE-A88A-4A25-B516-65CD85FA498D Q53705286-ED4ACE22-B789-49F2-AD6A-B37949842107 Q55107050-E32DB2F0-47F0-49BA-AB54-2A2D7A243F3F Q57300237-E59573C4-B888-459B-B97C-7EEC12941C60 Q58801325-5D6980BF-E954-413A-B40B-740CE1778C39

P2860

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.

http://www.wikidata.org/entity/Q35834087

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@ast

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@en

type

label

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@ast

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@en

prefLabel

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@ast

CAR-Engineered NK Cells Target ...... rived Glioblastoma Stem Cells.

@en

P1433

Q35834087-48DD4873-371A-4DDB-8978-9D7217104F70

P1476

Q35834087-4EC23B96-E5B7-4822-8ED9-BEA592F3E2BD

P2093

Q35834087-11D9C834-520A-4F01-825D-780AEE66E1EC

Q35834087-351BD114-C9CD-462C-BB74-E9C190346A3F

Q35834087-357AA2EA-7D3B-4021-8ED9-007F13387A71

Q35834087-7B2CB303-6057-4EA8-9458-E61BD27372DB

Q35834087-7D92F6B6-A930-42CA-A36F-4A47E8C8B075

Q35834087-8B1568B6-B783-43A2-B24A-920CBE67942F

Q35834087-8C532FB2-7963-466A-86A8-8E452655A857

Q35834087-9BCDBEE2-5778-4FEE-AC46-CFB8DFA083AF

Q35834087-9FEF1996-5673-45D5-A608-0A14FCF33726

Q35834087-B5841C42-8229-48E8-A7EB-3112B1825A4E

P2860

Q35834087-1AF035F4-EF00-4E5F-B4CA-56B7474A04EE

Q35834087-1C4885C4-E3C9-44CC-8134-182F4A0A4B00

Q35834087-1FE3F3FB-DFCA-4AA9-A90E-C07BA29BCA43

Q35834087-398ADC54-7CBB-454F-8C34-9E0ADE5D931C

Q35834087-4816CBE6-3293-49A8-92A9-57FDB065D0EA

Q35834087-4A40AD22-4F95-49BA-8898-79642AD6A14B

Q35834087-5C998EEB-1474-4560-A5EC-1E2986CB3AF7

Q35834087-5E217142-5111-4B3A-BEAC-503579982BE5

Q35834087-618B8068-3C11-423B-B86B-0ADDA38B3BD0

Q35834087-63355770-4DFB-44C0-B0C9-F58EAA97F127

P2888

Q35834087-368B81F6-B8C9-404F-86E8-B56511DCB5CA

P304

Q35834087-C07471AA-83F6-457B-8DB4-C71633DFC26D

P31

Q35834087-8D251B9D-8F82-4BD9-A122-2308E05281B7

P356

Q35834087-D67694B7-59D9-4A07-9F7B-5B528997D95A

P407

Q35834087-DD8220B7-E991-404B-8274-DF58D03CED29

P478

Q35834087-3577B44A-53EB-4D59-85ED-1727A949E4A7

P50

Q35834087-131D027D-9DCE-4967-8A6B-FAF43675DDE8

Q35834087-B4EEFDCB-B367-4C2E-8841-C16CDECCB597

P577

Q35834087-E652B503-3190-4A07-B78B-4A60998B0858

P5875

Q35834087-775156D8-933A-460B-9F2E-22F4D043EF20

P698

Q35834087-16B5B10B-68C6-4592-B48F-280E74AED73E

P921

Q35834087-6C275932-43FA-479C-88A5-CF26BCFE56E2

P932

Q35834087-34B91307-C5B6-42DD-95A7-25E66F2F8A73

P356

P1433

Scientific Reports

P1476

CAR-Engineered NK Cells Target ...... erived Glioblastoma Stem Cells

@en

P2093

Aaron Victor

http://www.w3.org/2001/XMLSchema#string

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

E Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Ichiro Nakano

http://www.w3.org/2001/XMLSchema#string

Jianfeng Han

http://www.w3.org/2001/XMLSchema#string

Jianhong Chu

http://www.w3.org/2001/XMLSchema#string

Jianhua Yu

http://www.w3.org/2001/XMLSchema#string

Jianying Zhang

http://www.w3.org/2001/XMLSchema#string

Joseph C Glorioso Iii

http://www.w3.org/2001/XMLSchema#string

Michael A Caligiuri

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor

Epidermal growth factor-related peptides and their receptors in human malignancies

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

Cancer immunotherapy comes of age

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

P2888

P304

11483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP11483

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Justus B. Cohen

P577

2015-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279987754

http://www.w3.org/2001/XMLSchema#string

P698

26155832

http://www.w3.org/2001/XMLSchema#string

P921

P932

4496728

http://www.w3.org/2001/XMLSchema#string